Phathom Pharmaceuticals Inc (PHAT) FinancialsPHATPhathom Pharmaceuticals Inc

Evaluating the bottom line, Phathom Pharmaceuticals, Inc. maintains a gross margin of 79.68%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -5.34%, while the net margin is -23.67%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively PHAT converts its operational activities into shareholder value.

In the context of the broader market, PHAT competes directly with industry leaders such as SGMT and ETRA. With a market capitalization of $598.67M, it holds a significant position in the sector. When comparing efficiency, PHAT's gross margin of 79.68% stands against SGMT's N/A and ETRA's N/A. Such benchmarking helps identify whether Phathom Pharmaceuticals, Inc. is trading at a premium or discount relative to its financial performance.

Phathom reported a record net revenue of $74.3 million for Q2 2026, an 88% increase year-over-year, but net income remains negative with a loss of $17.58 million in Q2 2026.